期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 21, 期 14, 页码 -出版社
MDPI
DOI: 10.3390/ijms21144910
关键词
DNA damage response; glioblastoma; DDR inhibitors
资金
- Associazione Italiana per la Ricerca sul Cancro (AIRC)-IG2016 [19069]
- MIUR-JPI-HDHL-NUTRICOG-MiTyrAge [PRIN_2015LZE994_005]
- Italian Ministry of Health [RF-2016-02362022, RF-2016-02363460]
- PhD programme in Molecular and Cellular Biology, University of Rome Tor Vergata
Glioblastoma multiforme (GBM) is a severe brain tumor whose ability to mutate and adapt to therapies is at the base for the extremely poor survival rate of patients. Despite multiple efforts to develop alternative forms of treatment, advances have been disappointing and GBM remains an arduous tumor to treat. One of the leading causes for its strong resistance is the innate upregulation of DNA repair mechanisms. Since standard therapy consists of a combinatory use of ionizing radiation and alkylating drugs, which both damage DNA, targeting the DNA damage response (DDR) is proving to be a beneficial strategy to sensitize tumor cells to treatment. In this review, we will discuss how recent progress in the availability of the DDR kinase inhibitors will be key for future therapy development. Further, we will examine the principal existing DDR inhibitors, with special focus on those currently in use for GBM clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据